CytomX to Present at Upcoming Investor Conferences
2017年2月3日 - 6:05AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, today announced that the company’s management
will participate in two upcoming investor conferences.
- Bob Goeltz, chief financial officer, will participate in a
company fireside chat at the 6th Annual LEERINK Partners Global
Healthcare Conference on Thursday, February 16, 2017, at 1:00 p.m.
ET.
- Sean McCarthy, D. Phil., president and chief executive officer,
will participate in a company fireside chat at the RBC Capital
Markets 2017 Global Healthcare Conference on Thursday, February 23,
2017, at 1:35 p.m. ET.
A live audio webcast for each event will be available through
the Investors and News section of CytomX's website. An
archived replay will be available for 90 days following the
event.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company
pioneering a novel class of investigational antibody therapeutics
based on its Probody technology platform. The company uses the
platform to create proprietary cancer immunotherapies against
clinically-validated targets, as well as to develop first-in-class
investigational cancer therapeutics against novel targets. CytomX
believes that its Probody platform has the potential to improve the
combined efficacy and safety profile of monoclonal antibody
modalities, including cancer immunotherapies, antibody drug
conjugates and T-cell-recruiting bispecific antibodies. Probody
therapeutics are designed to take advantage of unique conditions in
the tumor microenvironment to enhance the tumor-targeting features
of an antibody and reduce drug activity in healthy tissues.
The company’s investigational Probody therapeutics address
clinically-validated cancer targets in immuno-oncology, such as
PD-L1, against which the clinical candidate CX-072 is directed, as
well as novel targets, such as CD-166, that are difficult to drug
without causing damage to healthy tissues. In addition to its
proprietary programs, CytomX is collaborating with strategic
partners including AbbVie, Bristol-Myers Squibb Company, Pfizer
Inc., MD Anderson Cancer Center, and ImmunoGen, Inc. For more
information, visit www.cytomx.com.
Forward-Looking StatementsThis press release
includes forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors that are difficult to predict, may be beyond our
control, and may cause the actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied in such
statements. Accordingly, you should not rely on any of these
forward-looking statements. Our Probody platform is beginning
clinical development, and the process by which clinical development
could potentially lead to an approved product is long and subject
to significant risks and uncertainties. Projected net cash
utilization and capital resources are subject to substantial risk
of variance based on a wide variety of factors that can be
difficult to predict. Applicable risks and uncertainties
include those relating to our preclinical research and development,
clinical development, and other risks identified under the heading
"Risk Factors" included in our filings with the SEC. The
forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Corporate Communications Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024